Overview of Herbal Supplements

Total Page:16

File Type:pdf, Size:1020Kb

Overview of Herbal Supplements Chapter 4: Overview of Herbal Supplements 5 Contact Hours By: Joanne S. Richards, B.S., R.Ph., J.D., RAC Author Disclosure: Joanne S. Richards and Elite Professional Questions regarding statements of credit and other customer service Education, LLC. do not have any actual or potential conflicts of issues should be directed to 1-888-666-9053. This lesson is $20.00. interest in relation to this lesson. Educational Review Systems is accredited by the Universal Activity Number (UAN): 0761-9999-16-127-H01-T Accreditation Council of Pharmacy Education (ACPE) Activity Type: Knowledge-based as a provider of continuing pharmaceutical education. Initial Release Date: June 1, 2016 This program is approved for 5 hours (0.5 CEUs) of Expiration Date: June 1, 2018 continuing pharmacy education credit. Proof of Target Audience: Pharmacy Technicians in a community-based participation will be posted to your NABP CPE profile within 4 to 6 setting. weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete To Obtain Credit: A minimum test score of 70 percent is needed the course evaluation to receive continuing pharmacy education credit. to obtain a credit. Please submit your answers either by mail, fax, or online at PharmacyTech.EliteCME.com. Learning objectives Define what an herbal supplement is in the United States. Generally discuss the issues and problems associated with Discuss the extent of use worldwide of herbal medicine. scientific testing and reporting of research results on herbal Outline suggested reasons patients do not disclose their use of supplements. herbal supplements to their health care providers. Discuss the historical and current uses for 13 common herbal Explain why all health care providers should incorporate use of supplements. herbal supplements into the patient’s medical and medication Discuss side effects and recommended dosages of 13 common histories. herbal supplements. Itemize factors that have an effect on the quality and therapeutic Give examples of common herbal supplements that interfere with efficacy of herbal products. medical lab tests. Describe the differences between U.S. regulatory review processes Give examples of common herbal supplements that affect blood for drugs and herbal products. coagulation and aggregation. List the information required and prohibited by the FDA on herbal Give examples of common herbal supplements that interfere with supplement labels. liver enzymes, liver function, and drugs metabolized in the liver. Introduction There are numerous health risks and misconceptions associated This course provides an overview of herbal medications and the with herbal supplements, e.g., potential adverse effects, drug-drug regulatory process associated with their manufacture and marketing. interactions, lab test interactions, and dose-to-dose content variability, With some of the more frequently used herbals, it further provides to name a few. More often than not, patients and health care specific information on safety, effectiveness, interactions and side practitioners are unaware of these potential problems. The physician effects. may even be unaware that the patient is taking them at all, either Today, more than ever, patients receive information from and have because the patient does not voluntarily disclose the information or access to a variety of medications, some of which may dramatically because the health care practitioner does not ask. affect the success or failure of the medical treatment they receive. Thus, it is important for those involved in each step in the continuum This lesson emphasizes how important it is for health care providers to of patient care to be aware not only of the extent and type of problems inquire and for patients to disclose what herbal medications the patient they may encounter when patients consume herbal medicines, but also is taking and to be able to discuss and explain the potential risks and to consistently obtain such information from patients and be able to benefits associated with them. discuss the benefits and dangers associated with these commonly used health aids. Herbal supplement use [14, 32, 34, 35, 64, 82, 100, 122, 147, 160-162, 184] Compounds extracted from plants, animals, or microorganisms have cancer drugs. Plants having medicinal or therapeutic properties, flavor, been used to treat or prevent disease for centuries. Examples include and scent used to maintain or improve health are often called herbal digitalis, reserpine, morphine, penicillin, and vinca alkaloid anti- products, botanical products, or phytomedicines. Page 35 PharmacyTech.EliteCME.com As defined by Congress in the Dietary Supplement Health and ● The belief that the physician lacks interest or knowledge about Education Act of 1994, a dietary supplement is a product (other than herbals. tobacco) that: ● Not being asked by their practitioner about taking herbals. ● Is intended to supplement the diet. ● Their use of herbals is a cultural mainstay of therapy and they do ● Contains one or more dietary ingredients (e.g., vitamins, minerals, not even think to disclose it. herbs or other botanicals, amino acids, or essential fatty oils). ● A lack of awareness that herbal medicines can interact with and ● Is intended to be taken by mouth as a pill, capsule, tablet, or liquid. alter the therapeutic efficacy of conventional medications. ● Is labeled on the front panel as being a dietary supplement. To further complicate the issue, detailed information on herbal Recently, the World Health Organization estimated that 70-80 percent supplements is often outside the general knowledge base of medical of people worldwide rely on herbal medicines for some part of their prescribers, either because of limited formal training or inaccurate primary health care, but only 23-40 percent of these people tell their or biased information sources. In addition to physicians and nurses physician. Statistics reveal that the likelihood of consuming herbal who don’t ask patients about their use of herbal medicines, some medicines is higher in persons of higher education and income. community pharmacists who on a daily basis are in a key position Possible explanations for patients’ non-disclosure include: to assess interactions with conventional drugs also may rarely ask ● The belief that natural medicines have no adverse effects. patients about their use of herbals. ● The belief that over-the-counter and non-mainstream medicines Thus, because of the prevalent use, misconceptions, invalid assumptions, are irrelevant to their doctor’s overall treatment plan and outcome. and lack of patient information, it is critical to educate patients and all ● Their concern about a negative reaction from their practitioner. those in the health care delivery chain on the effects that herbal medicine can have on therapeutic outcomes. Pharmacology of herbal supplements [30, 75, 82, 101, 109, 127, 162] In the United States, current good manufacturing practices (cGMPs) while in the body. In addition to a drug’s chemical properties, applicable to food manufacturing are the only quality-control pharmacokinetics depends on patient-related factors, such as renal regulations on herbal medicines. The final marketed product, however, function, genetic makeup, sex, and age. These factors are often used to is impacted by more than just satisfying current good manufacturing predict how a drug will affect a specific population. practices. Pharmacodynamics can be simply explained as what a drug does to Other factors that influence the quality and thus the potential for the body. It involves receptor binding and sensitivity, post-receptor reliable therapeutic effectiveness of herbals include: effects, and chemical interactions. Physiologic changes caused by ● Identification and collection of the botanical source (e.g. leaf, root, disorders, aging, or other drugs can affect a drug’s pharmacodynamics. flower). The pharmacologic response depends on the drug binding to its target. ● Isolation, purification, and concentration of one or more active The concentration of the drug at the receptor site influences the drug’s ingredients. effect. ● Contaminants, e.g., pesticides and micro-organisms. Bioavailability refers to the extent and rate at which the drug or ● Active ingredient source substitution. metabolite enters systemic circulation, thereby accessing the site of ● Preparation process of specimens (e.g., solutions, desiccation, action. Bioavailability of a drug is determined by the properties of the trituration). dosage form, the product’s design, and its method of manufacture. ● Excipients used. Differences in bioavailability among formulations of a given drug can ● Storage conditions. have clinical significance, so knowing whether drug formulations are ● Final product formulation (e.g., solution, suspension, powder, equivalent is essential. tablet, capsules). Chemical equivalence means that the drug products contain the same The impact of these factors is best explained by understanding how active compound and in the same amount. Inactive ingredients in drugs work in our bodies. Pharmacokinetics, pharmacodynamics, and drug products may differ. Bioequivalence means that when the drug bioavailability are terms used to explain this process. is given to the same patient in the same dosage regimen, equivalent Pharmacokinetics is the study of the processes of drug absorption, concentrations of drug in plasma and tissues are achieved. distribution,
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0020892 A1 Thompson Et Al
    US 20170020892A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0020892 A1 Thompson et al. (43) Pub. Date: Jan. 26, 2017 (54) USE OF NEGATIVE MODULATORS OF Related U.S. Application Data GABA RECEPTORS CONTAINING ALPHAS SUBUNITS AS FAST ACTING (60) Provisional application No. 61/972,446, filed on Mar. ANTDEPRESSANTS 31, 2014. (71) Applicant: University of Maryland, Baltimore, Publication Classification Baltimore, MD (US) (51) Int. Cl. A 6LX 3/557 (2006.01) (72) Inventors: Scott Thompson, Baltimore, MD (US); A6II 3/53 (2006.01) Mark D. Kvarta, Ellicott City, MD A6II 45/06 (2006.01) (US); Adam Van Dyke, Baltimore, MD (52) U.S. Cl. (US) CPC ........... A61 K3I/55.17 (2013.01); A61K 45/06 (2013.01); A61 K3I/53 (2013.01) (73) Assignee: University of Maryland, Baltimore, Baltimore, MD (US) (57) ABSTRACT Embodiments of the disclosure include methods and com (21) Appl. No.: 15/300,984 positions related to treatment of one or more medical conditions with one or more negative modulators of GABA (22) PCT Filed: Mar. 31, 2015 receptors. In specific embodiments, depression and/or Sui cidability is treated or ameliorated or prevented with one or (86) PCT No.: PCT/US2O15/023667 more negative modulators of GABA receptors, such as a S 371 (c)(1), partial inverse agonist of a GABA receptor comprising an (2) Date: Sep. 30, 2016 alpha5 subunit. Patent Application Publication Jan. 26, 2017. Sheet 1 of 12 US 2017/002O892 A1 ×1/ /|\ Patent Application Publication Jan. 26, 2017. Sheet 3 of 12 US 2017/002O892 A1 & Patent Application Publication Jan.
    [Show full text]
  • An Investigation Into Pro-Apoptotic Targets in Experimental Glaucoma and the Neuroprotective Effects of Ginkgo Biloba in Retinal Ganglion Cells
    An investigation into pro-apoptotic targets in experimental glaucoma and the neuroprotective effects of Ginkgo biloba in retinal ganglion cells Abeir Baltmr MB ChB, FRCS (Glasg) A thesis submitted to University College London for the degree of Doctor of Medicine (Research) 2012 Glaucoma and Retinal Neurodegeneration Research Group Visual Neuroscience Institute of Ophthalmology 1 Declaration I, Abeir Baltmr, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I confirm that this has been indicated in the thesis. Abeir Baltmr 2 Abstract Ginkgo biloba has been advocated as a neuroprotective agent for several years in glaucoma. In this study, immunohistochemistry was used to identify known potential molecular targets of Ginkgo biloba related to retinal ganglion cell (RGC) apoptosis in experimental glaucoma, including amyloid precursor protein (APP), Aß, cytochrome c, caspase-3 and tumor necrosis factor receptor-1 (TNF-R1). Furthermore, using apoptotic inducers related to mechanisms implicated in glaucoma, namely Dimethyl sulphoxide (DMSO), ultraviolet C (UVC) and Sodium Azide (NaN3), the effects of the terpenoid fraction of Ginkgo biloba (Ginkgolide A, Ginkgolide B and Bilobalide) were investigated separately in cultured retinal ganglion cells (RGC-5). Cell viability was determined by 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenyltetrazolium bromide (MTT) assay and morphological analysis of DMSO treated RGC-5 was performed using Hoechst 33342 stain. Immunohistochemistry showed a strong inverse correlation between Aß and APP in ocular hypertension (OHT) animals, with APP and Aß accumulation peaking at 1 and 12 weeks after intraocular pressure (IOP) elevation respectively. Cytochrome c and TNF-R1 expression peaked at 3 weeks, and active caspase 3 activity at 12 weeks after IOP elevation.
    [Show full text]
  • Ginkgolide B Increases Hydrogen Sulfide and Protects Against Endothelial Dysfunction in Diabetic Rats
    4 DISEASE-RELATED CHANGES IN BLOOD VESSELS Croat Med J. 2015;56:4-13 doi: 10.3325/cmj.2015.56.4 Ginkgolide B increases Guo-Guang Wang1*, Qing- Ying Chen2*, Wei Li1, Xiao- hydrogen sulfide and protects Hua Lu1, Xue Zhao1 1Department of Pathophysiology, against endothelial dysfunction Wannan Medical College, Wuhu, in diabetic rats People’s Republic of China 2General Hospital of Jinan Military Command, Jinan, People’s Republic of China *Contributed equally to the study. Aim To evaluate the effect of ginkgolide B treatment on vascular endothelial function in diabetic rats. Methods The study included four groups with 15 male Sprague-Dawley rats: control group; control group treat- ed with ginkgolide B; diabetic group; and diabetic treat- ed with ginkgolide B. The activity of superoxide dismutase (SOD), malondialdehyde content, and nicotinamide ade- nine dinucleotide phosphate (NADPH) oxidase subunits, and glutathione peroxidase 1 (GPX1) protein expression were determined in aortic tissues. Vasoconstriction to phe- nylephrine (PHE) and vasorelaxation to acetylcholine (Ach) and sodium nitroprusside (SNP) were assessed in aortic rings. Nitric oxide (NO) and hydrogen sulfide (H2S) were measured, as well as cystathionine γ lyase (CSE) and cys- tathionine β synthetase (CBS) protein expression, and en- dothelial nitric oxide synthase (eNOS) activity. Results Diabetes significantly impaired PHE-induced va- soconstriction and Ach-induced vasorelaxation (P < 0.001), reduced NO bioavailability and H2S production (P < 0.001), SOD activity, and GPX1 protein expression (P < 0.001), and increased malondialdehyde content and NADPH oxidase subunits, and CSE and CBS protein expression (P < 0.001). Ginkgolide B treatment improved PHE vasoconstriction and Ach vasorelaxation (P < 0.001), restored SOD (P = 0.005) and eNOS (P < 0.001) activities, H2S production (P = 0.044) and decreased malondialdehyde content (P = 0.014).
    [Show full text]
  • Mixed Antagonistic Effects of the Ginkgolides at Recombinant Human R1 GABAC Receptors
    Neuropharmacology 63 (2012) 1127e1139 Contents lists available at SciVerse ScienceDirect Neuropharmacology journal homepage: www.elsevier.com/locate/neuropharm Mixed antagonistic effects of the ginkgolides at recombinant human r1 GABAC receptors Shelley H. Huang a, Trevor M. Lewis b, Sarah C.R. Lummis c, Andrew J. Thompson c, Mary Chebib d, Graham A.R. Johnston a, Rujee K. Duke a,* a Discipline of Pharmacology, School of Medical Sciences, Faculty of Medicine, University of Sydney, Australia b School of Medical Sciences, University of New South Wales, Australia c Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom d Faculty of Pharmacy, University of Sydney, Australia article info abstract Article history: The diterpene lactones of Ginkgo biloba, ginkgolides A, B and C are antagonists at a range of Cys-loop Received 11 July 2011 receptors. This study examined the effects of the ginkgolides at recombinant human r1 GABAC recep- Received in revised form tors expressed in Xenopus oocytes using two-electrode voltage clamp. The ginkgolides were moderately 18 June 2012 potent antagonists with IC sinthemM range. At 10 mM, 30 mM and 100 mM, the ginkgolides caused Accepted 24 June 2012 50 rightward shifts of GABA doseeresponse curves and reduced maximal GABA responses, characteristic of noncompetitive antagonists, while the potencies showed a clear dependence on GABA concentration, Keywords: indicating apparent competitive antagonism. This suggests that the ginkgolides exert a mixed-type Ginkgolide Bilobalide antagonism at the r1 GABAC receptors. The ginkgolides did not exhibit any obvious use-dependent Mixed-antagonism inhibition. Fitting of the data to a number of kinetic schemes suggests an allosteric inhibition as Use-dependent a possible mechanism of action of the ginkgolides which accounts for their inhibition of the responses GABAr receptor without channel block or use-dependent inhibition.
    [Show full text]
  • Total Syntheses of Ginkgolide B
    Total Syntheses of Ginkgolide B O HO O HO O H O t-Bu Me O HO O O H Brooks Maki May 23, 2005 Outline • What? – Background of Ginkgolides • Why? – Points of interest concerning Ginkgolide B • Who? (When?) – Corey’s racemic synthesis (1988) – Corey’s enantioselective synthesis (1988) – Crimmins’ racemic synthesis (2000) • How? – 2 total syntheses – 1 formal synthesis Isolation and Characterization • Ginkgolides A, B, C, and M were isolated from O HO O the root bark of Ginkgo biloba by Furukawa in R2 O H O 1932. t-Bu Me O R1 • Nakanishi and co-workers identified structures R3 of these diterpenes in 1967. O O H Ginkgolide A - R1 = OH, R2 = H, R3 = H Ginkgolide B - R1 = OH, R2 = OH, R3 = H • Also in 1967, Okabe and colleagues published Ginkgolide C - R1 = OH, R2 = OH, R3 = OH X-ray crystallography studies confirming Ginkgolide M - R1 = H, R2 = OH, R3 = OH structure and absolute stereochemistry of the Ginkgolide J - R1 = OH, R2 = H, R3 = OH ginkgolides. H O O O • Bilobalide (in 1971) and Ginkgolide J (in O O 1987) have been discovered as other members OH O t-Bu of the ginkgolide family. H OH Furukawa, S. Sci. Papers Inst. Phys. Chem. Res. Tokyo 1932, 19, 27. Bilobalide Nakanishi, K. Pure Appl. Chem. 1967, 14, 89-113. Sakabe, N.; Takada, S.; Okabe, K. J. Chem. Soc., Chem. Commun. 1967, 259-261 Ginkgo Biloba: The Source • Oldest fossil records from 270 million years ago • Basically unchanged since the Jurassic period. • Extracts known to have medicinal value for nearly 2500 years (China, Japan, and India) • Survived atomic blast at Hiroshima in 1945.
    [Show full text]
  • Beneficial Effects of Ginkgo Biloba Extract on Insulin Signaling Cascade, Dyslipidemia, and Body Adiposity of Diet-Induced Obese Rats
    Brazilian Journal of Medical and Biological Research (2014) 47(9): 780-788, http://dx.doi.org/10.1590/1414-431X20142983 ISSN 1414-431X Beneficial effects of Ginkgo biloba extract on insulin signaling cascade, dyslipidemia, and body adiposity of diet-induced obese rats R.M. Banin1, B.K.S. Hirata1, I.S. Andrade2, J.C.S. Zemdegs2, A.P.G. Clemente4, A.P.S. Dornellas2, V.T. Boldarine2, D. Estadella3, K.T. Albuquerque5, L.M. Oyama2, E.B. Ribeiro2 and M.M. Telles1 1Departamento de Cieˆncias Biolo´gicas, Universidade Federal de Sa˜o Paulo, Diadema, SP, Brasil 2Disciplina de Fisiologia da Nutric¸a˜o, Departamento de Fisiologia, Universidade Federal de Sa˜o Paulo, Sa˜o Paulo, SP, Brasil 3Departamento de Biocieˆncias, Universidade Federal de Sa˜o Paulo, Baixada Santista, SP, Brasil 4Faculdade de Nutric¸a˜o, Universidade Federal de Alagoas, Maceio´, AL, Brasil 5Curso de Nutric¸a˜o, Universidade Federal do Rio de Janeiro, Macae´, RJ, Brasil Abstract Ginkgo biloba extract (GbE) has been indicated as an efficient medicine for the treatment of diabetes mellitus type 2. It remains unclear if its effects are due to an improvement of the insulin signaling cascade, especially in obese subjects. The aim of the present study was to evaluate the effect of GbE on insulin tolerance, food intake, body adiposity, lipid profile, fasting insulin, and muscle levels of insulin receptor substrate 1 (IRS-1), protein tyrosine phosphatase 1B (PTP-1B), and protein kinase B (Akt), as well as Akt phosphorylation, in diet-induced obese rats. Rats were fed with a high-fat diet (HFD) or a normal fat diet (NFD) for 8 weeks.
    [Show full text]
  • Calcium-Engaged Mechanisms of Nongenomic Action of Neurosteroids
    Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Rebas, Elzbieta, Tomasz Radzik, Tomasz Boczek, and Ludmila Zylinska. 2017. “Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids.” Current Neuropharmacology 15 (8): 1174-1191. doi:10.2174/1570159X15666170329091935. http:// dx.doi.org/10.2174/1570159X15666170329091935. Published Version doi:10.2174/1570159X15666170329091935 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160234 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA 1174 Send Orders for Reprints to [email protected] Current Neuropharmacology, 2017, 15, 1174-1191 REVIEW ARTICLE ISSN: 1570-159X eISSN: 1875-6190 Impact Factor: 3.365 Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids BENTHAM SCIENCE Elzbieta Rebas1, Tomasz Radzik1, Tomasz Boczek1,2 and Ludmila Zylinska1,* 1Department of Molecular Neurochemistry, Faculty of Health Sciences, Medical University of Lodz, Poland; 2Boston Children’s Hospital and Harvard Medical School, Boston, USA Abstract: Background: Neurosteroids form the unique group because of their dual mechanism of action. Classically, they bind to specific intracellular and/or nuclear receptors, and next modify genes transcription. Another mode of action is linked with the rapid effects induced at the plasma membrane level within seconds or milliseconds. The key molecules in neurotransmission are calcium ions, thereby we focus on the recent advances in understanding of complex signaling crosstalk between action of neurosteroids and calcium-engaged events.
    [Show full text]
  • Preparation Process for Oral Dissolving Film of Ginkgolide B for Treatment of Alzheimer's Disease
    Acta Medica Mediterranea, 2020, 36: 1223 PREPARATION PROCESS FOR ORAL DISSOLVING FILM OF GINKGOLIDE B FOR TREATMENT OF ALZHEIMER'S DISEASE JUNTONG ZHOU1, QINMEI XU1, YUE WANG1, 2, ZHENPENG WANG3, JIAYANG LI4, SHAN YU1, KEXIN LIU1, CHI LI1, SHUHUI LI1, YUAN ZHANG1, XINTONG QU1, YE TIAN1, ZHAOXUAN FENG1, QING HUO1, 2* 1Biochemical Engineering College, Beijing Union University, Beijing, P. R. China - 2Beijing Key Laboratory of Biomass Waste Resource Utilization, Beijing, P. R. China - 3Institute of Chemistry, Chinese Academy of Sciences, Beijing, P.R. China - 4CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing, China ABSTRACT Objective: Ginkgolide B (GB) has been applied to cardiovascular diseases in clinic with its anti-oxidative and anti-aging effects. GB plays a neuroprotective role in models of various diseases. A study showns that Aβ1-42 induces oxidative damage to the cellular biomolecules, which are associated with AD pathology, and are protected by the pre-treatment of GB against Aβ-toxicity. We prepared the oral dissolving film (ODF) of GB by tape casting. The influence of film forming material, plasticizer and defoamer on the perfor - mance of the ODF of GB was studied. ODF has better adherence and is easy to take, which provides certain reference value for future nerve agents. Methods: The preparation parameters were as follows: 35mg GB was dissolved with 70ml of distilled water and mixed well, which was followed by the addition of 0.5g of glycerol as the plasticizer. After complete dissolution, 2g of hydroxypropyl methylcel - lulose was added as the film forming material.
    [Show full text]
  • Handbook of Schizophrenia Spectrum Disorders, Volume III
    Handbook of Schizophrenia Spectrum Disorders, Volume III Michael S. Ritsner Editor Handbook of Schizophrenia Spectrum Disorders, Volume III Therapeutic Approaches, Comorbidity, and Outcomes 123 Editor Michael S. Ritsner Technion – Israel Institute of Technology Rappaport Faculty of Medicine Haifa Israel [email protected] ISBN 978-94-007-0833-4 e-ISBN 978-94-007-0834-1 DOI 10.1007/978-94-007-0834-1 Springer Dordrecht Heidelberg London New York Library of Congress Control Number: 2011924745 © Springer Science+Business Media B.V. 2011 No part of this work may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher, with the exception of any material supplied specifically for the purpose of being entered and executed on a computer system, for exclusive use by the purchaser of the work. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com) Foreword Schizophrenia Spectrum Disorders: Insights from Views Across 100 years Schizophrenia spectrum and related disorders such as schizoaffective and mood dis- orders, schizophreniform disorders, brief psychotic disorders, delusional and shared psychotic disorders, and personality (i.e., schizotypal, paranoid, and schizoid per- sonality) disorders are the most debilitating forms of mental illness, worldwide. There are 89,377 citations (including 10,760 reviews) related to “schizophrenia” and 2118 (including 296 reviews) related to “schizophrenia spectrum” in PubMed (accessed on August 12, 2010). The classification of these disorders, in particular, of schizophrenia, schizoaf- fective and mood disorders (referred to as functional psychoses), has been debated for decades, and its validity remains controversial.
    [Show full text]
  • Ginkgolide B Modulates BDNF Expression in Acute Ischemic Stroke
    Laboratory Investigation J Korean Neurosurg Soc 60 (4) : 391-396, 2017 https://doi.org/10.3340/jkns.2016.1010.018 pISSN 2005-3711 eISSN 1598-7876 Ginkgolide B Modulates BDNF Expression in Acute Ischemic Stroke Hu Wei, M.D.,1 Tao Sun, M.D.,2 Yanghua Tian, M.D.,3 Kai Wang, M.D.3 Department of Neurology,1 Affiliated Provincial Hospital of Anhui Medical University, Hefei, China Department of Neurology,2 Nanjing General Hospital of Nanjing Command, Nanjing, China Department of Neurology,3 the First Hospital of Anhui Medical University, Hefei, China Objective : To investigate the neuroprotective effects of Ginkgolide B (GB) against ischemic stroke-induced injury in vivo and in vitro, and further explore the possible mechanisms concerned. Methods : Transient middle cerebral artery occlusion (tMCAO) mice and oxygen-glucose deprivation/reoxygenation (OGD/R)- treated N2a cells were used to explore the neuroprotective effects of GB. The expression of brain-derived neurotrophic factor (BDNF) was detected via Western blot and qRT-PCR. Results : GB treatment (4 mg/kg, i. p., bid) significantly reduced neurological deficits, water content, and cerebral infarct volume in tMCAO mice. GB also significantly increased Bcl-2/Bax ratio, reduced the expression of caspase-3, and protected against OGD/ R-induced neuronal apoptosis. Meanwhile, GB caused the up-regulation of BDNF protein in vivo and in vitro. Conclusion : Our data suggest that GB might protect the brain against ischemic insult partly via modulating BDNF expression. Key Words : Stroke · Ginkgolide B · Brain-derived neurotrophic factor · Apoptosis. INTRODUCTION detailed understanding of the mechanisms involved will have a substantial effect in the optimization and development of Ischemic stroke is the most common acute neurologic dis- treatment strategies.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,916,910 Lai (45) Date of Patent: Jun
    USOO591.6910A United States Patent (19) 11 Patent Number: 5,916,910 Lai (45) Date of Patent: Jun. 29, 1999 54 CONJUGATES OF DITHIOCARBAMATES Middleton et al., “Increased nitric oxide synthesis in ulcer WITH PHARMACOLOGICALLY ACTIVE ative colitis” Lancet, 341:465-466 (1993). AGENTS AND USES THEREFORE Miller et al., “Nitric Oxide Release in Response to Gut Injury Scand. J. Gastroenterol., 264:11-16 (1993). 75 Inventor: Ching-San Lai, Encinitas, Calif. Mitchell et al., “Selectivity of nonsteroidal antiinflamatory drugs as inhibitors of constitutive and inducible cyclooxy 73 Assignee: Medinox, Inc., San Diego, Calif. genase” Proc. Natl. Acad. Sci. USA, 90:11693–11697 (1993). 21 Appl. No.: 08/869,158 Myers et al., “Adrimaycin: The Role of Lipid Peroxidation in Cardiac Toxicity and Tumor Response' Science, 22 Filed: Jun. 4, 1997 197:165-167 (1977). 51) Int. Cl. ...................... C07D 207/04; CO7D 207/30; Onoe et al., “Il-13 and Il-4 Inhibit Bone Resorption by A61K 31/27; A61K 31/40 Suppressing Cyclooxygenase-2-Dependent ProStaglandin 52 U.S. Cl. .......................... 514/423: 514/514; 548/564; Synthesis in Osteoblasts' J. Immunol., 156:758–764 548/573; 558/235 (1996). 58 Field of Search ..................................... 514/514, 423; Reisinger et al., “Inhibition of HIV progression by dithio 548/565,573; 558/235 carb” Lancet, 335:679–682 (1990). Schreck et al., “Dithiocarbamates as Potent Inhibitors of 56) References Cited Nuclear Factor KB Activation in Intact Cells' J. Exp. Med., 175:1181–1194 (1992). U.S. PATENT DOCUMENTS Slater et al., “Expression of cyclooxygenase types 1 and 2 in 4,160,452 7/1979 Theeuwes ..............................
    [Show full text]
  • Ginkgolide B‑Induced AMPK Pathway Activation Protects Astrocytes by Regulating Endoplasmic Reticulum Stress, Oxidative Stress
    MOLECULAR MEDICINE REPORTS 23: 457, 2021 Ginkgolide B‑induced AMPK pathway activation protects astrocytes by regulating endoplasmic reticulum stress, oxidative stress and energy metabolism induced by Aβ1‑42 JING WANG1‑4, YAN DING1,2, LINWU ZHUANG1,2, ZHENZHONG WANG3,4, WEI XIAO3,4 and JINGBO ZHU1,2 1School of Food Science and Technology and 2Institute of Chemistry and Applications of Plant Resources, Dalian Polytechnic University, Dalian, Liaoning 116034; 3Jiangsu Kanion Pharmaceutical Co. Ltd.; 4State Key Laboratory of Pharmaceutical New‑tech for Chinese Medicine, Lianyungang, Jiangsu 222000, P.R. China Received July 20, 2020; Accepted January 11, 2021 DOI: 10.3892/mmr.2021.12096 Abstract. Ginkgolide B (GB), the diterpenoid lactone levels of MDA and ROS in astrocytes, while compound C compound isolated from the extracts of Ginkgo biloba leaves, reversed the anti‑oxidative effect and the involvement of GB significantly improves cognitive impairment, but its potential in maintaining energy metabolism in astrocytes. Finally, GB pharmacological effect on astrocytes induced by β‑amyloid decreased the expression levels of the endoplasmic reticulum (Aβ)1‑42 remains to be elucidated. The present study aimed to stress (ERS) proteins and the apoptotic protein CHOP and investigate the protective effect and mechanism of GB on astro‑ increased both mRNA and protein expression of the compo‑ cytes with Aβ1‑42‑induced apoptosis in Alzheimer's disease nents of the energy metabolism‑related AMPK/peroxisome (AD). Astrocytes obtained from Sprague Dawley rats were proliferator‑activated receptor γ coactivator 1α/peroxisome randomly divided into control, Aβ, GB and GB + compound C proliferator‑activated receptor α and anti‑oxidation‑related groups.
    [Show full text]